Fortrea Holdings Inc. reports news on its role as a global contract research organization serving the life sciences industry. The company provides phase I-IV clinical trial management, clinical pharmacology and consulting services for biopharmaceutical, biotechnology, medical device and diagnostic customers.
Recurring Fortrea updates include quarterly and annual financial results, book-to-bill trends, guidance, debt and capital actions, executive and board matters, equity award disclosures and technology used in clinical trial operations. Company announcements also cover platforms such as Fortrea Intelligent Technology and Xcellerate, which support trial workflow, oversight and site-facing processes.
Fortrea (Nasdaq: FTRE) will release its first quarter 2026 financial results before the market opens on Tuesday, May 5, 2026.
The company will host a conference call at 8:00 a.m. ET that day; participants should pre-register to receive dial-in details and a unique PIN. A live webcast will be available at investors.fortrea.com, with a replay posted in Events and Presentations after the call.
Fortrea (Nasdaq: FTRE) unveiled Fortrea Intelligent Technology™ (FIT) on April 7, 2026, a suite of AI-enhanced solutions built on the Xcellerate® platform to automate workflows, streamline oversight and deliver near-real-time, role-based insights for sponsors, investigator sites and study teams.
FIT is arranged into three pillars — Lifecycle, Foresight and Companion — and supports clinical pharmacology, clinical development and medical device programs across full-service, functional service and select SaaS deployments.
Fortrea (Nasdaq: FTRE) granted inducement awards of 130,000 restricted stock units (RSUs) on March 10, 2026 to four newly hired employees. The RSUs vest in three equal annual installments beginning March 10, 2027, subject to continuous employment and the Amended and Restated 2025 Inducement Award Plan.
The awards were made under Nasdaq Listing Rule 5635(c)(4) and are intended as an inducement material to each individual becoming a new employee.
Fortrea (Nasdaq: FTRE) reported fourth-quarter 2025 revenue of $660.5M and full-year 2025 revenue of $2,723.4M. GAAP net loss was $(32.5M) in Q4 and $(986.2M) for the year, reflecting a $797.9M goodwill impairment in H1 2025.
Adjusted EBITDA was $54.0M in Q4 and $189.9M for 2025; adjusted net income was $40.4M for the year. Trailing-12-month book-to-bill was 1.02x with backlog of $7,728.0M. Cash was $174.6M and gross debt $1,066.3M. 2026 guidance targets revenue of $2,550M–$2,650M and adjusted EBITDA of $190M–$220M.
Fortrea (Nasdaq: FTRE) expanded its executive team on Feb 17, 2026: Oren Cohen, MD, shifts to a sole Chief Medical Officer role focused on medical strategy, scientific leadership, ethics and governance across Fortrea’s portfolio. Scott Dove, PhD joins as President of Clinical Pharmacology Services to lead early clinical development across Fortrea’s global clinics.
The move is positioned to deepen client scientific partnerships and accelerate early-phase development capabilities while keeping both executives on Fortrea’s Executive Committee.
Fortrea (Nasdaq: FTRE) will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026.
The company will host a conference call at 8:00 am ET the same day with a Q&A. Participants should register on the Fortrea Investor Relations website, join at least 10 minutes early, and can access a live webcast. A replay will be posted in the events and presentations section.
Fortrea (Nasdaq: FTRE) updated its presentation time at the J.P. Morgan Annual Healthcare Conference to 11:15 am PST on Tuesday, January 13, 2026. CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations Tracy Krumme will participate. A live webcast and replay will be available via the company’s Investor Relations "Events" page. Investors seeking one-on-one meetings should contact their banking representatives.
Fortrea (Nasdaq: FTRE) announced that CEO Anshul Thakral, CFO Jill McConnell, and SVP Investor Relations Tracy Krumme will present at the J.P. Morgan Annual Healthcare Conference in San Francisco.
The presentation and Q&A are scheduled for Tuesday, January 13, 2025 at 5:15 pm PST. A live webcast and replay will be available in the company’s Events section on Fortrea’s Investor Relations website. Investors seeking one-on-one meetings are asked to contact their banking representatives.
Fortrea (Nasdaq: FTRE) announced on December 10, 2025 the grant of inducement restricted stock units (RSUs) to two newly hired employees. The award totals 245,000 RSUs granted on December 10, 2025.
The RSUs vest in three equal annual installments beginning December 10, 2026, subject to continuous employment through each vesting date, and are governed by the company’s Amended and Restated 2025 Inducement Award Plan and the applicable award agreements. The grants were made under Nasdaq Listing Rule 5635(c)(4) as inducements to employment.
SCTbio and Fortrea (FTRE) announced a strategic collaboration on December 4, 2025 to align CDMO manufacturing and CRO clinical development for cell and gene therapies. The partnership aims to streamline development timelines, harmonize GMP manufacturing readiness with trial logistics, and reduce program risk by enabling early protocol alignment, supply‑chain resilience, and coordinated planning from first‑in‑human trials toward commercialization.
The agreement stresses synchronized execution across manufacturing, apheresis, viral vectors and global clinical operations to accelerate delivery of advanced therapies to patients.